Logo image of NXL

NEXALIN TECHNOLOGY INC (NXL) Stock Fundamental Analysis

NASDAQ:NXL - Nasdaq - US65345B2016 - Common Stock - Currency: USD

2.57  -0.03 (-1.15%)

After market: 2.58 +0.01 (+0.39%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to NXL. NXL was compared to 191 industry peers in the Health Care Equipment & Supplies industry. While NXL has a great health rating, there are worries on its profitability. NXL is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NXL has reported negative net income.
In the past year NXL has reported a negative cash flow from operations.
NXL had negative earnings in each of the past 5 years.
NXL had a negative operating cash flow in each of the past 5 years.
NXL Yearly Net Income VS EBIT VS OCF VS FCFNXL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -2M -4M -6M

1.2 Ratios

With a Return On Assets value of -105.66%, NXL is not doing good in the industry: 85.26% of the companies in the same industry are doing better.
The Return On Equity of NXL (-112.04%) is worse than 66.32% of its industry peers.
Industry RankSector Rank
ROA -105.66%
ROE -112.04%
ROIC N/A
ROA(3y)-320.51%
ROA(5y)-1671.7%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NXL Yearly ROA, ROE, ROICNXL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K

1.3 Margins

NXL has a Gross Margin of 78.82%. This is amongst the best in the industry. NXL outperforms 92.11% of its industry peers.
In the last couple of years the Gross Margin of NXL has declined.
NXL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 78.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.25%
GM growth 5YN/A
NXL Yearly Profit, Operating, Gross MarginsNXL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K -5K

More info and screens

8

2. Health

2.1 Basic Checks

NXL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NXL has more shares outstanding
There is no outstanding debt for NXL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NXL Yearly Shares OutstandingNXL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2M 4M 6M
NXL Yearly Total Debt VS Total AssetsNXL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2M 4M 6M

2.2 Solvency

NXL has an Altman-Z score of 42.22. This indicates that NXL is financially healthy and has little risk of bankruptcy at the moment.
NXL has a better Altman-Z score (42.22) than 97.89% of its industry peers.
There is no outstanding debt for NXL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 42.22
ROIC/WACCN/A
WACC9.12%
NXL Yearly LT Debt VS Equity VS FCFNXL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 2M -2M 4M

2.3 Liquidity

NXL has a Current Ratio of 16.39. This indicates that NXL is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of NXL (16.39) is better than 97.89% of its industry peers.
A Quick Ratio of 15.86 indicates that NXL has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 15.86, NXL belongs to the best of the industry, outperforming 98.42% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 16.39
Quick Ratio 15.86
NXL Yearly Current Assets VS Current LiabilitesNXL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2M 4M 6M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for NXL have decreased by -3.55% in the last year.
The Revenue has grown by 24.68% in the past year. This is a very strong growth!
NXL shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -22.72% yearly.
EPS 1Y (TTM)-3.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.19%
Revenue 1Y (TTM)24.68%
Revenue growth 3Y-22.72%
Revenue growth 5YN/A
Sales Q2Q%80.15%

3.2 Future

Based on estimates for the next years, NXL will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.59% on average per year.
NXL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 163.23% yearly.
EPS Next Y2.5%
EPS Next 2Y14.57%
EPS Next 3Y14.59%
EPS Next 5YN/A
Revenue Next Year56.86%
Revenue Next 2Y104.82%
Revenue Next 3Y163.23%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NXL Yearly Revenue VS EstimatesNXL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 500K 1M 1.5M 2M
NXL Yearly EPS VS EstimatesNXL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NXL. In the last year negative earnings were reported.
Also next year NXL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NXL Price Earnings VS Forward Price EarningsNXL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NXL Per share dataNXL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as NXL's earnings are expected to grow with 14.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.57%
EPS Next 3Y14.59%

More info and screens

0

5. Dividend

5.1 Amount

NXL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEXALIN TECHNOLOGY INC

NASDAQ:NXL (1/28/2025, 8:00:02 PM)

After market: 2.58 +0.01 (+0.39%)

2.57

-0.03 (-1.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-28 2022-11-28/bmo
Earnings (Next)N/A N/A
Inst Owners2.61%
Inst Owner Change4.56%
Ins Owners21.9%
Ins Owner Change65.73%
Market Cap33.05M
Analysts45
Price Target3.06 (19.07%)
Short Float %3.08%
Short Ratio0.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 203.91
P/FCF N/A
P/OCF N/A
P/B 6.67
P/tB 7.02
EV/EBITDA N/A
EPS(TTM)-0.64
EYN/A
EPS(NY)-0.43
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS0.01
BVpS0.39
TBVpS0.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -105.66%
ROE -112.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 78.82%
FCFM N/A
ROA(3y)-320.51%
ROA(5y)-1671.7%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.25%
GM growth 5YN/A
F-Score5
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.39
Quick Ratio 15.86
Altman-Z 42.22
F-Score5
WACC9.12%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.19%
EPS Next Y2.5%
EPS Next 2Y14.57%
EPS Next 3Y14.59%
EPS Next 5YN/A
Revenue 1Y (TTM)24.68%
Revenue growth 3Y-22.72%
Revenue growth 5YN/A
Sales Q2Q%80.15%
Revenue Next Year56.86%
Revenue Next 2Y104.82%
Revenue Next 3Y163.23%
Revenue Next 5YN/A
EBIT growth 1Y-35.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-125.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-121.82%
OCF growth 3YN/A
OCF growth 5YN/A